Raman Pharma is a UK based MHRA and VMD Licensed Wholesaler supplying to the Human and Veterinary Market. We are a family run company ambitiously changing the face of the Pharmaceutical and Veterinary Market alike in order to serve the needs of our customers and their patients.
Our Philosophy and business are structured around the requirements of our customers and we are committed to giving them our upmost attention and care. We believe in delivering quality and value to our customers wherever they may be.
The Herbal Horse and Pet is a South African manufacturer of a very innovative range of supplements for horses, dogs and cats. Their philosophy of using a large number of different ingredients in small amounts mimics nature in that the healing effect of the ingredients is maximised while undesirable side-effects are minimised. These unique formulations, in conjunction with 21st century scientific research and techniques are what they call “cutting edge nature”.
They are manufactured in a GMP Compliant Factory and has a large following from riders and pet owners across the world. Please follow the link to the website – www.theherbalhorse.co.uk to see all the amazing blogs and the ability to purchase these products online. The Equine and Pet Range were introduced to the UK Market in September 2014 by Raman Pharma to give the UK a taste of the future in equine and companion animal nutritional supplements.
Over the next fortnight PSNC and the other national community pharmacy representative bodies will be making the case for pharmacy at both the Labour and Conservative Party Conferences. PSNC, the Association of Independent Multiple Pharmacies (AIM), the Company Chemists’ Association (CCA) and the National Pharmacy Association (NPA) are jointly hosting roundtable events at both conferences...
As we head towards the UK’s planned exit from the European Union, the Government’s guidance and messaging for the public and those involved in the medicines supply chain has evolved. Below is a round-up of recent events that community pharmacy teams need to be aware of. Patient messaging revised The patient information about a no-deal...
Department of Health and Social Care (DHSC) has today granted the following initial list of price concessions: Drug Pack Size Price concession Betahistine 8mg tablets 84 £1.65 Betahistine 16mg tablets 84 £2.99 Co-careldopa 12.5mg/50mg tablets 90 £10.73 Cyclizine 50mg/1ml solution for injection ampoules 5 £14.00 Escitalopram 10mg tablets 28 £3.19 Ibandronic acid 150mg tablets 1...
Morningside and Advanz, the manufacturers of Fluoxetine 10mg, 30mg and 40mg capsules, are currently experiencing temporary disruptions. Please see a table below which summarises the overall fluoxetine availability: Supplies are available from specialist importers on an ‘unlicensed’ basis. Ensure that where a prescriber wishes you to dispense an import, prescriptions are annotated ‘Special Order’ and...
The NHS Community Pharmacist Consultation Service (CPCS) will commence on 29th October 2019 and the Toolkit to support pharmacy teams to provide the service has just been published on the NHSBSA website. The Toolkit has been developed by NHS England and NHS Improvement (NHSE&I), with input from the Urgent Care Delivery and Implementation Group (a group of...
Pfizer, the sole supplier of Provera tablets, are experiencing manufacturing delays, and are out of stock of the 100mg tablets until week ending 8th November 2019. Provera 200mg and 400mg tablets remain available, but Pfizer say ‘they are unable to bridge the gap without going out of stock’. For guidance on alternative agents and management...
It has come to PSNC’s attention that inaccurate information has been circulating about the processing and reimbursement of dental prescriptions (FP10D) with stamped drug information. Some pharmacy teams have reported that they had heard that the NHS Business Service Authority (NHSBSA) ignores handwritten quantities on stamped prescriptions unless the quantity specified is initialled or countersigned...
The Public Accounts Committee (PAC) has today published a report of its investigation into penalty charge notices in healthcare, calling for an overhaul of the system which it considers “not fit for purpose”. The PAC is made up of a group of cross-party MPs; the Committee launched an inquiry after it became concerned that penalty...
PSNC has published Briefing 043/19: Pharmacy Quality Scheme – Foot and eye screening (retinopathy) checks for patients with diabetes to assist community pharmacy contractors with getting ready to meet the diabetes quality criterion of the Pharmacy Quality Scheme (PQS), which contractors need to start working towards from 1st October 2019. The Briefing explains how to...
A new Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update (Vol 13 Issue 1 August 2019) has been published and includes articles on: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping Fingolimod (Gilenya▼): increased risk of congenital malformations; new contraindication...
Public list of companies in the UK who have had their licence/registration to manufacture or wholesale medicines/ingredients revoked or suspended.
Data on the time taken by MHRA to assess clinical trial applications and substantial amendments.
List of field safety notices (FSNs) from medical device manufacturers from 09 to 13 September 2019.
Pharmacy, prescription-only (POM), and general sale list (GSL) medicines: apply to move your medicine to a different classification.
MHRA draws a distinction between regulatory function and clinical use of products.
Monthly PDF editions of the Drug Safety Update newsletter from MHRA and its independent advisor the Commission on Human Medicines.
Fingolimod is associated with an increased risk of major congenital malformations including cardiac, renal, and musculoskeletal defects, when used in pregnancy. Women of childbearing potential must use effective contraception during fingolimod treatment and for 2 months after discontinuation.
Cases of pigmentary maculopathy leading to visual impairment have been reported with pentosan polysulfate, particularly after long-term use at high doses. Ensure patients taking pentosan polysulfate have regular ophthalmic examinations and ask them to promptly seek medical advice in case of visual changes.
Prescribers should be alert for neuropsychiatric reactions in patients taking montelukast and carefully consider the benefits and risks of continuing treatment if they occur.
A letter was sent to advise healthcare professionals about a restriction to the indication and route of administration for Mitomycin-C Kyowa 40 mg following the observation of increased sub-visible particles in the drug product on storage. A letter was also sent to notify healthcare professionals of a risk of medication error with various Santen eye drop products during the period of transition to new bottles.
An alert was issued advising against use of Dermapen 3 and Dermapen Cryo Sterile single use needle cartridge tips for Dermapen 3 since their safety cannot be verified.
Guidance for marketing authorisation holders on drafting direct healthcare professional communications (DHPCs) or 'dear Dr letters', including the template.
Medicines that were granted a positive opinion under the early access to medicines scheme (EAMS) which has now expired.
MHRA transactions over £500 made using the government procurement card (GPC).
Information on Medicines and Healthcare products Regulatory Agency spending over £25,000.
Manufactured by CME (a BD company) – function may be affected by fluid getting into the pump and building up over time because of specific cleaning and disinfection practices.
What you need to know about the regulation of medical devices in the UK if we leave the EU with no deal.
We are reviewing our approach to how we engage and involve patients in the work of the Medicines and Healthcare products Regulatory Agency (MHRA).
Marketing authorisations granted in August 2019
Parallel import licenses granted in August 2019
We are updating the system to simplify and streamline the application process.
Reporting against VMD published standards up to 31 August 2019.
Guidance on applying for an authorisation to manufacture veterinary medicines.
For a marketing authorisation holder only; how to report a defect with a veterinary medicine.
Product defect recall alert for Isathal 10 mg/g eye drops, suspension for dogs, cats and rabbits by Dechra Veterinary Products.
The VMD is experiencing problems receiving and sending emails.
How to legally run a business that deals with the wholesale of animal medicines (veterinary medicinal products) and the WDA Register.
Information for the pharmaceutical industry on new timetables and process improvements for national applications for MAs, ATCs and VHRs.
Web services, such as the Special Imports System and Adverse Event Reporting will be unavailable due to essential electrical maintenance.
Reported problems with the supply of an animal medicine and the date when the issue is expected to be resolved.
You must get permission to export certain drugs and medicines.
As of 9 August 2019 the VMD email addresses will be @vmd.gov.uk.
Details of seizure notice issued to Tudor House Animal Care Ltd, Wolverhampton, West Midlands. Published in August 2019.
Details of the improvement notice issued to Castlehill Veterinary Clinic, Dungannon, County Tyrone. Published in August 2019.
Availability of flunixin solutions for injection.
Report of the ten products for which most Special Import and Special Treatment Certificates (SIC and STC) have been issued by VMD in the UK.
Marketing Authorisations Veterinary Information Service (MAVIS) Hub edition 111.
The Veterinary Products Committee (VPC) is looking to appoint four new members.
This document contains the following information: Veterinary Medicines Directorate annual report and accounts 2018 to 2019.
How to comply with the exemption from the Veterinary Medicines Regulations that allow certain animal medicines to be sold without an authorisation.
The committee has recommended seven medicines for approval at its September 2019 meeting.
Tresiba significantly reduced the rate of severe hypoglycaemia by 80% and nocturnal symptomatic hypoglycaemia by 37%.
The findings support the prescription of SSRI antidepressants in a wider group of participants than previously thought.
only 7% of children with targetable mutations were able to access the appropriate adult drug in a study.
The coveted Pharma Digital Partner award was won by Emma Prosser from MSD.
Adult smoking rates fell 2.2% from January to July 2019, the equivalent of 200 fewer smokers an hour.
Facebook and Instagram have announced that they will remove posts promoting ‘miracle’ cures and get-slim-quick products.
'Don’t Risk Your Research' aims to raise awareness of the risks incompetence poses to patients, clinical research and organisations.
The designation was based on the Phase II NOBILITY study.
Type II diabetes costs the NHS £8.8 billion a year.
Novartis has also submitted to the EMA for approval in the disease, non-radiographic axial spondyloarthritis.
The recommendation was made based partly on data from the HELP-03 Study, in which Takhzyro reduced the mean number of monthly HAE attacks by 87%.
Research on the topic is vital yet sparse, as data in this area remain limited.
The therapeutics will address key co-morbidities for individuals living with the disease.
The company will not conduct any further trials.
Unit 2 Fleet Business Park, Sandy Lane, Church Crookham, Fleet, Hampshire, GU52 8BF
Pharmaceutical and Veterinary Licensed Distributor. WDA (H) 43703 & WDA (V) 43703.
- +44 (0)1252 260 460.
- +44 (0)1276 469 290
Monday to Friday - 09:30 – 18:30
Saturday & Sunday - Closed, Online Ordering Available